Hard to believe. SNTA went from an under the radar biotech with potential to a crashing failure because of immature mid-term data to to the hottest stock at next week's ESMO. It seems that the sane thing to do is go on vacation with no Internet connection......come back and SNTA will be $12. Or be $10. With a real partnership and future buyout. Slamming this down to $6, resulted in the faint-hearted running for the hills. The real investor is laughing.
I never count my chickens before they hatch, but I do feel a little better about SNTA each passing quarter. The company has done a very good job executing and also communicating with the medical and investment communities. And of course the insider buys show good commitment. I've sold in/out of SNTA a few times early on, so some of my shares are "free" ...I feel lucky about that.
I'm surprised they haven't partnered before this. Do you others think this might be because they would be very open to entertaining the right BO offer sooner than later. Or is that just wishful thinking on my part? Don't get me wrong, as much as I'd love a BO and sooner than later, I'm certainly not counting on it ...just fun speculation, because it is a possibility.
I'm long SNTA and for my situation I may add if elections or some worldwide event creates a market crash or big pullback on all stocks.
I hope the presentation goes well but this is biotech and the street can see results much different than the company. As long as I have been a biotech investor, I still wonder how this information can't leak out prior to the data being released. One would think that if patients were responding well to the drug that someone would notice the improvement and tip off investors.
That being said, I guess no one knows the results other than the company, although the bias has been to the buy side of the stock.